Daiana Ibarretxe1, Josefa Girona1, Núria Plana1, Anna Cabré1, Raimón Ferré1, Núria Amigó2, Sandra Guaita1, Roger Mallol2, Mercedes Heras1, Luis Masana3. 1. Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain; Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. 2. Biosfer Teslab, Reus and Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. 3. Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain; Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. Electronic address: luis.masana@urv.cat.
Abstract
BACKGROUND: PCSK9 is a pivotal molecule in the regulation of lipid metabolism. Previous studies have suggested that PCSK9 expression and its function in LDL receptor regulation could be altered in the context of diabetes. The aim was to assess PCSK9 plasma levels in patients with type 2 diabetes (T2DM) and other related metabolic disorders as well as its relation to the metabolomic profile generated by nuclear magnetic resonance (NMR) and glucose homeostasis. METHODS: There were recruited a total of 457 patients suffering from T2DM and other metabolic disorders (metabolic syndrome (MetS), obesity and atherogenic dyslipidaemia (AD) and other disorders). Anamnesis, anthropometry and physical examinations were conducted, and vascular and abdominal adiposity imaging were carried out. Biochemical studies were performed to determine PCSK9 plasma levels 6 weeks after lipid lowering drug wash-out in treated patients. A complete metabolomic lipid profile was also generated by NMR. The rs505151 and rs11591147 genetic variants of PCSK9 gene were identified in patients. RESULTS: The results showed that PCSK9 levels are increased in patients with T2DM and MetS (14% and 13%; p<0.005, respectively). Circulating PCSK9 levels were correlated with an atherogenic lipid profile and with insulin resistance parameters. PCSK9 levels were also positively associated with AD, as defined by lipoprotein particle number and size. The rs11591147 genetic variant resulted in lower levels of circulating PCSK9 and LDL cholesterol (LDL-C). CONCLUSIONS: PCSK9 plasma levels are increased in T2DM and MetS patients and are associated with LDL-C and other parameters of AD and glucose metabolism.
BACKGROUND:PCSK9 is a pivotal molecule in the regulation of lipid metabolism. Previous studies have suggested that PCSK9 expression and its function in LDL receptor regulation could be altered in the context of diabetes. The aim was to assess PCSK9 plasma levels in patients with type 2 diabetes (T2DM) and other related metabolic disorders as well as its relation to the metabolomic profile generated by nuclear magnetic resonance (NMR) and glucose homeostasis. METHODS: There were recruited a total of 457 patients suffering from T2DM and other metabolic disorders (metabolic syndrome (MetS), obesity and atherogenic dyslipidaemia (AD) and other disorders). Anamnesis, anthropometry and physical examinations were conducted, and vascular and abdominal adiposity imaging were carried out. Biochemical studies were performed to determine PCSK9 plasma levels 6 weeks after lipid lowering drug wash-out in treated patients. A complete metabolomic lipid profile was also generated by NMR. The rs505151 and rs11591147 genetic variants of PCSK9 gene were identified in patients. RESULTS: The results showed that PCSK9 levels are increased in patients with T2DM and MetS (14% and 13%; p<0.005, respectively). Circulating PCSK9 levels were correlated with an atherogenic lipid profile and with insulin resistance parameters. PCSK9 levels were also positively associated with AD, as defined by lipoprotein particle number and size. The rs11591147 genetic variant resulted in lower levels of circulating PCSK9 and LDL cholesterol (LDL-C). CONCLUSIONS:PCSK9 plasma levels are increased in T2DM and MetS patients and are associated with LDL-C and other parameters of AD and glucose metabolism.
Authors: Juan Pedro-Botet; Juan F Ascaso; Vivencio Barrios; Alejandro De la Sierra; Javier Escalada; Jesús Millán; Jose M Mostaza; Pablo Pérez-Martínez; Xavier Pintó; Jordi Salas-Salvadó; Pedro Valdivielso Journal: Diabetes Metab Syndr Obes Date: 2018-10-31 Impact factor: 3.168
Authors: Kari Antero Mäkelä; Juhani Leppäluoto; Jari Jokelainen; Timo Jämsä; Sirkka Keinänen-Kiukaanniemi; Karl-Heinz Herzig Journal: Front Physiol Date: 2019-04-30 Impact factor: 4.566
Authors: Maya S Safarova; Benjamin A Satterfield; Xiao Fan; Erin E Austin; Zhan Ye; Lisa Bastarache; Neil Zheng; Marylyn D Ritchie; Kenneth M Borthwick; Marc S Williams; Eric B Larson; Aaron Scrol; Gail P Jarvik; David R Crosslin; Kathleen Leppig; Laura J Rasmussen-Torvik; Sarah A Pendergrass; Amy C Sturm; Bahram Namjou; Amy Sanghavi Shah; Robert J Carroll; Wendy K Chung; Wei-Qi Wei; QiPing Feng; C Michael Stein; Dan M Roden; Teri A Manolio; Daniel J Schaid; Joshua C Denny; Scott J Hebbring; Mariza de Andrade; Iftikhar J Kullo Journal: NPJ Genom Med Date: 2019-02-11 Impact factor: 8.617
Authors: Aleksandr B Shek; Rano B Alieva; Ravshanbek D Kurbanov; Shavkat U Hoshimov; Ulugbek I Nizamov; Adolat V Ziyaeva Journal: Arch Med Sci Atheroscler Dis Date: 2019-07-18
Authors: Theodosios D Filippatos; Evangelos Liberopoulos; Maria Georgoula; Constantinos C Tellis; Alexandros D Tselepis; Moses Elisaf Journal: Arch Med Sci Atheroscler Dis Date: 2017-10-05